💥 Dragon Pharma

Cardiogen

✔️ Substance: Bioregulator Peptide
✔️ Price For: Vial 20 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma Cardiogen

IDENTITYCompoundBioregulator Peptide
ProductCardiogen
Strength20 mg
FormLyophilized Vial
ClassPeptide Bioregulator

PEPTIDE PROFILECategoryOrgan-Specific Peptide
Target SystemCardiovascular Tissue
OriginBioregulating Peptide Complex
FunctionCellular Regulation Support
Research AreaCardiac Tissue Biology

PHARMACOLOGYAdministrationSubcutaneous Injection
Peptide TypeBioregulator
Hormonal ActivityNone Direct
Anabolic ActivityNot Classified
Primary RoleCellular Adaptation Support

STORAGE & RECONSTITUTIONBrandDragon Pharma
Package20 mg Vial
Storage2–8°C Recommended
ProtectionLight & Moisture
PreparationReconstitution Required

ADMINISTRATION PROFILERouteSubcutaneous (SC)
UsageDaily Peptide Administration
TimingMorning or Evening Protocol
Duration4–12 Weeks Research Period
FrequencyDaily Administration

DOSING INFORMATIONResearch Dose100–500 mcg/day
Weekly Amount0.7–3.5 mg/week
Intermediate Use250 mcg/day
AdministrationSubcutaneous Injection
Duration4–12 Weeks

BODYBUILDING USAGEMain PurposeRecovery Support
Training PhaseHigh Volume Training Periods
CombinationRecovery Focused Protocols
Muscle EffectIndirect Recovery Support
PCTNot Required

USAGE FEATURESStart PeriodGradual Cellular Adaptation
Week 1–2Initial Peptide Activity
Week 3–8Support Phase
Week 8+Extended Recovery Protocol
StoppingNo Hormonal Restart Needed

MECHANISM OF ACTIONTargetCellular Regulatory Pathways
ActionPeptide Signal Modulation
TissueCardiovascular System
RecoveryCellular Adaptation Support
HormonesNo Direct Androgen Activity

PHARMACOKINETICSAbsorptionSubcutaneous Uptake
ReleasePeptide Signaling Activity
MetabolismProteolytic Breakdown
DurationShort Biological Activity
ClearancePeptide Metabolism Pathways

SAFETY PROFILEHormonal SuppressionNot Expected
Liver ToxicityLow Expected Risk
Cardiac MonitoringRecommended
Injection RiskSite Irritation Possible
Long Term DataLimited

CONTRAINDICATIONSPregnancyNot Recommended
AllergyAvoid Hypersensitivity
Medical ConditionsProfessional Evaluation
Injection SafetyMaintain Sterile Practice
MonitoringHealth Assessment

RECOVERY & DISCONTINUATIONPCTNot Applicable
Hormonal RecoveryNo HPTA Restart Required
StoppingGradual Protocol Completion
Recovery FocusMaintain Training Balance
Follow UpMonitor Individual Response

COMPATIBILITYRecovery StackPeptide Based Support
Training SupportHigh Volume Programs
NutritionProtein Adequate Diet
CombinationResearch Dependent
Hormonal CompoundsNo Direct Interaction Data

CHEMICAL PROFILECompoundBioregulator Peptide
Molecular TypePeptide Complex
FormulaNot Publicly Established
Molecular WeightNot Publicly Established
CASNot Available

OVERVIEW

Dragon Pharma Cardiogen 20 mg is a bioregulator peptide product designed for research focused on cardiovascular cellular regulation and recovery-related pathways. Unlike anabolic steroids, Cardiogen does not function through androgen receptor activation and does not provide direct anabolic effects.

BENEFITS

Supports cardiovascular tissue research
May assist cellular adaptation processes
Non-androgenic peptide profile
No direct HPTA suppression
Compatible with recovery-focused protocols
Useful during intensive training phases
Supports research into peptide regulation

POTENTIAL RISKS

Limited human clinical data
Possible injection site reactions
Individual peptide sensitivity
Need for sterile administration
Unknown long-term effects
Quality differences between suppliers

PERFORMANCE PROFILE

Recovery Support

75%

Cardio Support

70%

Training Adaptation

65%

Muscle Gain

20%

Hormonal Impact

10%

WHAT IS DRAGON PHARMA?

Dragon Pharma is a pharmaceutical brand recognized within the bodybuilding and sports performance market for producing a range of research-oriented and performance-related compounds. The brand portfolio includes injectable products, peptides and other specialty formulations marketed toward athletes and fitness communities.

WHY CHOOSE DRAGON PHARMA

Dragon Pharma products are selected by some users because of brand recognition, consistent packaging formats and availability of specialized compounds such as peptide-based formulations.

When evaluating any pharmaceutical or research compound, important factors include verified sourcing, product identification, storage conditions, responsible handling and scientific understanding of the compound profile.

CONCLUSION

Dragon Pharma Cardiogen 20 mg is a bioregulator peptide formulation designed for research into cardiovascular cellular regulation and tissue-specific peptide activity. Unlike anabolic androgenic steroids, Cardiogen does not directly stimulate androgen receptors, increase muscle protein synthesis through anabolic pathways, or require post-cycle therapy.

For bodybuilding audiences, this type of peptide is generally discussed as a recovery-support compound rather than a direct muscle-building agent. Its potential role is associated with cellular adaptation, cardiovascular support research and maintaining recovery capacity during demanding training periods.

Within bodybuilding communities, peptide bioregulators are commonly discussed as supportive compounds during demanding training periods where recovery capacity, cardiovascular function and long-term athlete wellness are important considerations.

Administration protocols commonly discussed in research environments involve subcutaneous use with controlled daily dosing over several weeks. Because peptide compounds may have limited clinical data compared with approved medications, responsible monitoring, product verification and scientific evaluation remain important.

DISCLAIMER

This information is provided for educational and scientific reference purposes only. It does not represent medical advice, treatment recommendations, or endorsement of non-approved pharmaceutical use. Peptide compounds should be evaluated according to scientific evidence, healthcare guidance and applicable regulations in the user's location.